The incidence of retinopathy of prematurity and steroid therapy for broncho-pulmonary dysplasia.
To determine whether prolonged dexamethasone therapy, used in the treatment of bronchopulmonary dysplasia (BPD), affects the incidence of retinopathy of prematurity (ROP), premature born infants (Gestational age < 33 weeks) treated or not with dexamethasone for BPD were retrospectively studied over a 5 year period. Although the dexamethasone treated group had a significant lower gestational age and a longer period of total ventilatory support there was no significant difference in incidence of ROP between the groups.
Jacobs
M A
MA
Department of Neonatology, University Hospital, Maastricht, The Netherlands.
Blanco
C E
CE
D000975:Antioxidants / Q000378:metabolism; D001997:Bronchopulmonary Dysplasia / Q000188:drug therapy*; D003907:Dexamethasone / Q000627:therapeutic use*; D005260:Female; D016166:Free Radical Scavengers; D005865:Gestational Age; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D008297:Male; D012178:Retinopathy of Prematurity / Q000453:epidemiology* / Q000517:prevention & control; D012189:Retrospective Studies
D000975:Antioxidants; D016166:Free Radical Scavengers; D005938:Glucocorticoids; D003907:Dexamethasone